Abstract
A phase II trial of continuous oral therapy with UFT, a combination of uracil and the 5-fluorouracil analogue 1-(2-tetrahydrofuryl)-5-fluorouracil (Futraful, Ftorafur), was conducted in 40 patients with advanced colorectal cancer and 18 patients with advanced gastric cancer. Six partial responses were seen in the 36 evaluable patients with colorectal cancer (response rate 16.6%; 95% confidence limits 6.4-32.8%), and one partial response was seen in the 16 evaluable patients with gastric cancer (response rate 6%; 95% confidence limits 0.27-30.2%). The overall toxicity of the treatment was low, and all patients were treated as outpatients. The results suggest that oral UFT has comparable activity to standard regimes of 5-fluorouracil, and because of the convenience of oral administration is a useful therapy in the management of patients with advanced colorectal cancer.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anttila M. I., Sotaniemi E. A., Kairaluoma M. I., Mokka R. E., Sundquist H. T. Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol. 1983;10(3):150–153. doi: 10.1007/BF00255750. [DOI] [PubMed] [Google Scholar]
- Au J. L., Wu A. T., Friedman M. A., Sadée W. Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat Rep. 1979 Mar;63(3):343–350. [PubMed] [Google Scholar]
- Blokhina N. G., Vozny E. K., Garin A. M. Results of treatment of malignant tumors with ftorafur. Cancer. 1972 Aug;30(2):390–392. doi: 10.1002/1097-0142(197208)30:2<390::aid-cncr2820300214>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
- Drewinko B., Yang L. Y. Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Rep. 1985 Dec;69(12):1391–1398. [PubMed] [Google Scholar]
- Erlichman C., Fine S., Wong A., Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol. 1988 Mar;6(3):469–475. doi: 10.1200/JCO.1988.6.3.469. [DOI] [PubMed] [Google Scholar]
- Fujii S., Ikenaka K., Fukushima M., Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gan. 1978 Dec;69(6):763–772. [PubMed] [Google Scholar]
- Fujii S., Kitano S., Ikenaka K., Shirasaka T. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gan. 1979 Apr;70(2):209–214. [PubMed] [Google Scholar]
- Lokich J. J., Ahlgren J. D., Gullo J. J., Philips J. A., Fryer J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989 Apr;7(4):425–432. doi: 10.1200/JCO.1989.7.4.425. [DOI] [PubMed] [Google Scholar]
- Wadler S., Schwartz E. L., Goldman M., Lyver A., Rader M., Zimmerman M., Itri L., Weinberg V., Wiernik P. H. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol. 1989 Dec;7(12):1769–1775. doi: 10.1200/JCO.1989.7.12.1769. [DOI] [PubMed] [Google Scholar]